Analyst predicts Biogen’s entry into hemophilia market could grow market
March 21, 2014 at 13:50 PM EDT
As Biogen Idec officially enteres the hemophila market with its first-ever approval for a drug to treat the blood clotting disorder, one analyst is already predicting the company will be able to increase the total number of patients taking such drugs due to its longer-lasting formulation...